Literature DB >> 6092633

Schizophreniform psychosis and adrenomyeloneuropathy.

A C James, P Kaplan, A Lees, J J Bradley.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6092633      PMCID: PMC1440255          DOI: 10.1177/014107688407701015

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   5.344


× No keyword cloud information.
  5 in total

1.  Adrenoleukodystrophy. A clinical and pathological study of 17 cases.

Authors:  H H Schaumburg; J M Powers; C S Raine; K Suzuki; E P Richardson
Journal:  Arch Neurol       Date:  1975-09

2.  The adrenoleukomyeloneuropathy complex: expression in four generations.

Authors:  B P O'Neill; L C Marmion; E R Feringa
Journal:  Neurology       Date:  1981-02       Impact factor: 9.910

3.  Adrenoleukodystrophy: elevated C26 fatty acid in cultured skin fibroblasts and correlation with disease expression in three generations of a kindred.

Authors:  B P O'Neill; H W Moser; L C Marmion
Journal:  Neurology       Date:  1982-05       Impact factor: 9.910

4.  Familial X-linked Addison disease as an expression of adrenoleukodystrophy (ALD): elevated C26 fatty acid in cultured skin fibroblasts.

Authors:  B P O'Neill; H W Moser; K M Saxena
Journal:  Neurology       Date:  1982-05       Impact factor: 9.910

5.  Nuclear magnetic resonance (NMR) imaging in white matter disease of the brain using spin-echo sequences.

Authors:  I R Young; C P Randell; P W Kaplan; A James; G M Bydder; R E Steiner
Journal:  J Comput Assist Tomogr       Date:  1983-04       Impact factor: 1.826

  5 in total
  2 in total

Review 1.  X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy.

Authors:  B M van Geel; J Assies; R J Wanders; P G Barth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

2.  Adrenoleukodystrophy: heterogeneity in two brothers.

Authors:  G M Elrington; D E Bateman; M J Jeffrey; N F Lawton
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-03       Impact factor: 10.154

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.